“Discover Alluvi Retatrutide, an innovative triple-action GIP, GLP-1, and glucagon receptor agonist for significant weight management and metabolic health. Learn about clinical trial results showing up to 24% weight loss and explore resources for patients and healthcare professionals.”
Welcome to Alluvi Healthcare. We believe in providing access to safe, research-supported solutions for real transformation. Alluvi Retatrutide is a groundbreaking, advanced peptide treatment that targets three key hormone receptors (GLP-1, GIP, and Glucagon) to enhance appetite control, improve metabolic efficiency, and boost fat burning.
RETATRUTIDE – PRE-FILLED PEN EVALUATION
Part of Alluvi Labs’ ongoing research program into advanced GLP-1 multi-agonist compounds.
This formulation is supplied in controlled batches for laboratory analysis of stability, compound behaviour, and injector system performance.
Not for human or veterinary consumption.
of stability, compound behaviour, and injector system performance.
Not for human or veterinary consumption.
Proven Data. Backed by Research.
Published studies have investigated GLP-1 multi-agonist compounds under controlled conditions.
Alluvi supplies Retatrutide pens exclusively for laboratory research and development.
Not for human or veterinary consumption.
All figures are derived from third party published studies and are shown only for academic context. All Alluvi products are supplied strictly for laboratory research purposes.
22.5%
Reference value drawn from published research on GLP-1 multi-agonist compounds.
Provided strictly as scientific context.
Participants consumed fewer calories per day without being instructed to diet – driven by decreased appetite and satiety signaling.
Provided strictly as scientific context.
28%
Reported value in published research relating to GLP-1 multi-agonist compounds.
Provided strictly as a scientific reference point
18.3 KG
Average weight loss during clinical trial period of 48 weeks on high-dose Retatrutide.
Example data point referenced in peer-reviewed studies for GLP-1 multi-agonists.
Alluvi does not promote or imply medical use of its products.
More than peptides.
A Complete Research Platform.
From research-grade compounds to structured data collection and nutritional analysis – Alluvi provides an integrated system designed for controlled research and development programs.
Not for human or veterinary consumption.